THE PREVENTION OF THE THROMBOSIS IN ONCOLOGY

Issue: 
5
Year: 
2016

O.V. Somonova
Dr.Sc. (Med.), Leading Research Scientist, Diagnostic Laboratory, N.N. Blokhin Russian Cancer Research Center (Moscow);
Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov
E-mail: somonova@mail.ru
A.L. Elizarova
Ph.D. (Biol.), Senior Research Scientist, Diagnostic Laboratory, N.N. Blokhin Russian Cancer Research Center (Moscow)
D.N. Kushlinsky
Ph.D. (Med.), Surgeon Cancers, Scientific Center for Obstetrics,
Gynecology and Perinatology named after Academician Kulakov (Moscow)
S.P. Kazakov
Dr.Sc. (Med.), Professor, Department of Immunology, Russian Medical Academy of Postgraduate Education (Moscow)

Malignant tumor increases the risk of deep vein thrombosis and pulmonary embolism in 4−7 times. Low molecular weight heparins are the basis of specific prevention of thromboembolic events in cancer patients. Adequate prevention and treatment of thrombotic complications in gynecological cancer patients before and after surgery and chemotherapy reduces the intensity of intravascular coagulation, reduces the incidence of venous thrombosis and prevent fatal pulmonary embolism, which enhances the antitumor treatment and improves the quality of life of these patients.

Keywords: 
Key words: gynecological cancer patients
hemostasis system
thrombotic complications
low molecular weight heparins.